arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

SCYNEXIS INC

SCYX
$5.30 ▲ +0.08 (+1.63%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

SCYNEXIS INC faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $264.6M
Dividend Yield
Revenue Growth 449.9%
Op. Margin -78.0%
ROIC -32.6%
FCF / Share $-0.11
Trailing P/E
Price / Book 4.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.60M
↑ +449.9%
Net Income Profit after all expenses
$-8.61M
↑ +59.6%
Operating Margin Operating profit as % of sales
-78.0%
↓ -250.5% 3th
FCF / Share Free cash flow per share
$-0.11
↑ +78.6%
Long-Term Debt Long-term obligations
$34.39M
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
6
Returns
29
Financial Health
19
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 54 quarters